Citius Pharmaceuticals (NASDAQ:CTXR) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.02, Zacks reports.

Citius Pharmaceuticals Stock Performance

Shares of NASDAQ CTXR traded up $0.02 during trading on Friday, reaching $0.76. The stock had a trading volume of 588,654 shares, compared to its average volume of 840,297. The company has a market cap of $20.74 million, a P/E ratio of -0.35 and a beta of 1.03. The business’s 50-day moving average price is $0.58 and its 200-day moving average price is $0.69. Citius Pharmaceuticals has a fifty-two week low of $0.47 and a fifty-two week high of $2.19.

Get Citius Pharmaceuticals alerts:

Institutional Investors Weigh In On Citius Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Heights Capital Management Inc. purchased a new stake in shares of Citius Pharmaceuticals during the fourth quarter worth approximately $622,000. XTX Topco Ltd grew its holdings in shares of Citius Pharmaceuticals by 572.8% during the fourth quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock worth $83,000 after purchasing an additional 91,196 shares during the last quarter. Asset Advisory Group Inc. acquired a new position in Citius Pharmaceuticals during the fourth quarter worth approximately $46,000. Finally, NewEdge Advisors LLC purchased a new stake in Citius Pharmaceuticals in the 2nd quarter valued at $40,000. Hedge funds and other institutional investors own 16.88% of the company’s stock.

Wall Street Analyst Weigh In

CTXR has been the topic of several analyst reports. Zacks Research upgraded shares of Citius Pharmaceuticals to a “hold” rating in a research report on Tuesday, May 19th. HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Citius Pharmaceuticals in a research report on Monday, May 18th. Wall Street Zen cut shares of Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $5.00.

Get Our Latest Research Report on CTXR

Citius Pharmaceuticals Company Profile

(Get Free Report)

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.

Featured Stories

• Five stocks we like better than Citius Pharmaceuticals
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
• Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
• NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
• Sandisk’s Margins Look Like Software. Can They Last?

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.